Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus
- PMID: 12083832
- DOI: 10.1006/viro.2002.1413
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus
Abstract
To determine molecular viral components which can induce innate immune responses in human peripheral blood mononuclear cells (PBMC), we investigated the anti-neoplastic agent Newcastle disease virus (NDV) and its two spike proteins hemagglutinin-neuraminidase (HN) and fusion protein (F). NDV was an excellent inducer in PBMC of IFN-alpha production and capable of inducing upregulation of plasma membrane expression of tumor necrosis factor related apoptosis inducing ligand (TRAIL). Viral replication was not required for these responses because NDV inactivated for 5 min by UV was as good as live NDV. NDV-modified and paraformaldehyde-fixed BHK cells could also trigger IFN-alpha and TRAIL induction, indicating that contacts of responder cells with NDV-modified cell surfaces are sufficient to induce these activities in PBMC. Antibodies against HN but not F were able to block these responses. Finally we could show that HN but not F induced IFN-alpha and TRAIL in PBMC. This was possible through the use of respective gene transfectants generated with the help of Semliki Forest virus (SFV) replicase-based DNA recombinant expression systems. Upon contact with BHK cells expressing HN but not F at their cell surface, human PBMC produced IFN-alpha and some cells, including monocytes and T lymphocytes, upregulated cell surface TRAIL expression.
(c) 2002 Elsevier Science (USA).
Similar articles
-
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.Int J Oncol. 2004 Mar;24(3):623-34. Int J Oncol. 2004. PMID: 14767547
-
Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA.Int J Oncol. 2003 Sep;23(3):673-80. Int J Oncol. 2003. PMID: 12888903
-
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules.Int J Oncol. 2004 Aug;25(2):293-302. Int J Oncol. 2004. PMID: 15254725
-
Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus.Biomedicines. 2022 Feb 28;10(3):562. doi: 10.3390/biomedicines10030562. Biomedicines. 2022. PMID: 35327364 Free PMC article. Review.
-
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.Cancer Immunol Immunother. 1996 Nov;43(3):190-4. doi: 10.1007/s002620050321. Cancer Immunol Immunother. 1996. PMID: 9001573 Review.
Cited by
-
Recombinant Newcastle disease virus (rL-RVG) triggers autophagy and apoptosis in gastric carcinoma cells by inducing ER stress.Am J Cancer Res. 2016 May 1;6(5):924-36. eCollection 2016. Am J Cancer Res. 2016. PMID: 27293989 Free PMC article.
-
Cell-type-specific innate immune response to oncolytic Newcastle disease virus.Viral Immunol. 2012 Aug;25(4):268-76. doi: 10.1089/vim.2012.0020. Epub 2012 Jul 18. Viral Immunol. 2012. PMID: 22808996 Free PMC article.
-
The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting.Cancer Immunol Immunother. 2010 Jul;59(7):989-99. doi: 10.1007/s00262-010-0821-5. Epub 2010 Feb 4. Cancer Immunol Immunother. 2010. PMID: 20130861 Free PMC article.
-
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.Oncol Lett. 2016 Nov;12(5):3344-3350. doi: 10.3892/ol.2016.5114. Epub 2016 Sep 9. Oncol Lett. 2016. PMID: 27900002 Free PMC article.
-
Oncolytic viruses: do they have a role in anti-cancer therapy?Clin Med Oncol. 2008;2:83-96. doi: 10.4137/cmo.s416. Epub 2008 Feb 9. Clin Med Oncol. 2008. PMID: 21892269 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources